Otonomy, Inc. Logo
Otonomy Appoints Jill Broadfoot to Board of Directors
August 19, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 04, 2021 16:16 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus ongoing with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss ongoing with results expected in mid-2022OTO-825 preclinical...
Otonomy, Inc. Logo
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
July 28, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy, Inc. Logo
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
June 15, 2021 07:30 ET | Otonomy, Inc.
OTO-413 demonstrated a higher proportion of responders than placebo based on multiple speech-in-noise hearing tests in dose escalation efficacy cohortExpansion study will support endpoint selection...
Otonomy, Inc. Logo
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
May 14, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 14, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy, Inc. Logo
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:17 ET | Otonomy, Inc.
OTO-313 Phase 2 trial in tinnitus initiated with results expected in mid-2022OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in...
Otonomy, Inc. Logo
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
May 04, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
Otonomy, Inc. Logo
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
April 28, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 19, 2021 07:30 ET | Otonomy, Inc.
SAN DIEGO, April 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Otonomy, Inc. Logo
Otonomy Announces Pricing of $30.1 Million Public Offering
April 07, 2021 22:02 ET | Otonomy, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...